MarketScreener Editorial Features Oncology Venture A/S Nasdaq Stockholm
Equities
End-of-day quote
Other stock markets
|
||
- SEK | - |
24/05 | Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial | CI |
06/05 | Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule | MT |
- Stock Market
- Equities
- ALLR Stock
- Stock
- News Oncology Venture A/S
- MarketScreener Editorial Features